KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Other Non-Current Liabilities (2016 - 2026)

Pacira BioSciences has reported Other Non-Current Liabilities over the past 17 years, most recently at $15.8 million for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities fell 10.12% year-over-year to $15.8 million; the TTM value through Mar 2026 reached $15.8 million, down 10.12%, while the annual FY2025 figure was $20.6 million, 22.33% up from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was $15.8 million at Pacira BioSciences, down from $20.6 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $56.5 million in Q1 2022 and troughed at $11.6 million in Q1 2023.
  • A 5-year average of $21.2 million and a median of $17.8 million in 2025 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 357.52% in 2022 and later tumbled 79.52% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $28.1 million in 2022, then plummeted by 51.74% to $13.6 million in 2023, then increased by 23.9% to $16.8 million in 2024, then increased by 22.33% to $20.6 million in 2025, then fell by 23.25% to $15.8 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for PCRX at $15.8 million in Q1 2026, $20.6 million in Q4 2025, and $17.8 million in Q3 2025.